Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) today announced that Paul Hamelin, Senior Vice President, Commercial Operations of Savient Pharmaceuticals will present a corporate update at the upcoming 28th Annual Cowen Healthcare Conference.
The presentation is scheduled to begin at 10:15 a.m. Eastern time on Tuesday, March 18th, 2008. The Conference will be held from March 17th to 20th at the Marriott Copley Place in Boston.
Individuals can listen to a live webcast of the presentation by logging on to the Investor Relations section of Savient Pharmaceuticals’ web site, http://www.savient.com. A replay of the webcast will be available on the company’s web site for 30 days.
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company’s product development candidate, Puricase (pegloticase) for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient enrollment was completed in March 2007; and the Phase 3 clinical studies were completed in October 2007. Pegloticase became the official generic name for Puricase assigned by the USAN Council replacing the previously used name of PEG-uricase. Savient's experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late-stage compounds and exploring co-promotion and co-development opportunities that fit the Company's expertise in specialty pharmaceuticals and biopharmaceuticals with an initial focus in rheumatology. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. Further information on Savient can be accessed by visiting: http://www.savient.com.
SVNT-G
Savient Pharmaceuticals, Inc.
Mary Coleman, Director, Investor
Relations
732-418-9300
information@savient.com
or
Lippert/Heilshorn
& Associates
Anne Marie Fields, 212-838-3777
afields@lhai.com